|

Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease

RECRUITINGN/ASponsored by Insel Gruppe AG, University Hospital Bern
Actively Recruiting
PhaseN/A
SponsorInsel Gruppe AG, University Hospital Bern
Started2026-08-01
Est. completion2028-07-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07777419

Summary

With this study, the investigators want to investigate how deep brain stimulation (DBS) affects various cognitive and psychiatric symptoms of Parkinson's disease (PD). In particular, they will examine whether stimulation of the left hemisphere has a different effect than stimulation of the right hemisphere on cognitive and psychiatric symptoms.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosed with Parkinson's disease
* Treated with subthalamic nucleus deep brain stimulation (STN-DBS)
* For part I: General research consent for the analysis of routine clinical data
* For part II of the study: ability to provide informed consent
* native German or French speaker
* Montreal Cognitive Assessment with score ≥ 20

Exclusion Criteria:

* Atypical Parkinsonism
* Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.)
* Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment
* Schizophrenia, ongoing substance abuse, bipolar disorder or autism
* For part II: Severe depressive disorder and/or suicidality
* Insufficient quality or lack of brain imaging data pre and/or post STN-DBS

Conditions2

Parkinson's DiseaseParkinsons Disease (PD)

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.